Epicypher, Inc.
Publicly observedResearch Triangle Park, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Research Triangle Park | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Epicypher, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | UWNWSADJYYZ3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Genomic profiling of drug-chromatin interactions for accelerated drug development research
USD 1,062,099.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant21 Aug 2026Publicly observed
NIH SBIR/STTR award: Scalable, single-molecule and single-cell chromatin accessibility profiling in primary immune cells
USD 999,268.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of novel epigenetic biomarkers and detection reagents for aging
USD 1,249,682.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant20 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of novel epigenetic biomarkers and detection reagents for aging
USD 1,249,147.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Asymmetric nucleosome substrates to advance the study of the histone code
USD 1,264,176.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Asymmetric nucleosome substrates to advance the study of the histone code
USD 1,264,176.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant25 Sept 2024Publicly observed
NIH SBIR/STTR award: Versatile platform for genome-wide R-loop mapping for aging and neurodegenerative disease research
USD 1,274,958.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant15 Aug 2024Publicly observed
NIH SBIR/STTR award: Versatile genomics platform for unbiased analysis of chromatin-associated RNAs and nascent transcripts
USD 1,267,289.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant1 Mar 2024Publicly observed
NIH SBIR/STTR award: Biochemical and genomic tools to study histone ADP ribosylation signaling
USD 1,274,280.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant19 Jul 2023Publicly observed
NIH SBIR/STTR award: Rapid and robust assay for measurement of in vivo activity of chromatin-interacting proteins
USD 1,008,869.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2023Publicly observed
NIH SBIR/STTR award: Epigenomic analysis of cell-free nucleosomes for cancer research
USD 1,047,610.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2023Publicly observed
NIH SBIR/STTR award: Epigenomic analysis of cell-free nucleosomes for cancer research
USD 1,047,610.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2023Publicly observed
NIH SBIR/STTR award: Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples
USD 1,017,618.00 · National Human Genome Research Institute · Source: NIH RePORTER (opens in a new tab)
- Grant10 Mar 2023Publicly observed
NIH SBIR/STTR award: Development of ultra-efficient antibodies for single cell mapping applications
USD 1,004,302.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.